Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The L-antigen family member 1 isoform A (LAGE-1A) peptide presented by histocompatibility leukocyte antigen A*02:01 is a tumor-associated antigen complex. LAGE-1A is a cancer-testis antigen overexpressed in various cancers with limited expression in normal tissues, primarily the testis. When presented by HLA-A*02:01, a common MHC class I molecule, it forms an epitope recognized by specific T cell receptors. This complex is a target for immunotherapy approaches, including engineered T cell therapies and bispecific antibodies, to redirect T cells to kill tumor cells expressing this antigen. IMCnyeso is an example of such a therapeutic agent. A potential safety concern is off-tumor toxicity due to LAGE-1A expression in the testis.
T cell redirection and activation
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on L-antigen family member 1 isoform A peptide presented by histocompatibility leukocyte antigen A*02 (LAGE-1A/HLA-A*02:01).